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Moderate lifelong overexpression 
of tuberous sclerosis complex 1 
(TSC1) improves health and survival 
in mice
Hong-Mei Zhang1, Vivian Diaz3, Michael E. Walsh4,5 & Yiqiang Zhang2
The tuberous sclerosis complex 1/2 (TSC1/2) is an endogenous regulator of the mechanistic target 
of rapamycin (mTOR). While mTOR has been shown to play an important role in health and aging, 
the role of TSC1/2 in aging has not been fully investigated. In the current study, a constitutive TSC1 
transgenic (Tsc1tg) mouse model was generated and characterized. mTORC1 signaling was reduced in 
majority of the tissues, except the brain. In contrast, mTORC2 signaling was enhanced in Tsc1tg mice. 
Tsc1tg mice are more tolerant to exhaustive exercises and less susceptible to isoproterenol-induced 
cardiac hypertrophy at both young and advanced ages. Tsc1tg mice have less fibrosis and inflammation 
in aged as well as isoproterenol-challenged heart than age-matched wild type mice. The female Tsc1tg 
mice exhibit a higher fat to lean mass ratio at advanced ages than age-matched wild type mice. More 
importantly, the lifespan increased significantly in female Tsc1tg mice, but not in male Tsc1tg mice. 
Collectively, our data demonstrated that moderate increase of TSC1 expression can enhance overall 
health, particularly cardiovascular health, and improve survival in a gender-specific manner.
mTOR is a central regulatory component for cell growth, proliferation, and cell size1. Through the interaction 
with a complex network of signaling pathways, mTOR regulates a wide spectrum of biological processes, includ-
ing autophagy, protein translation, metabolism, appetite, energy, stress responses, and inflammatory response/
immunity. The pivotal role of mTOR in health is reflected in the fact that deregulation of mTOR is associated 
with the development of many diseases, including inflammation, cancer, cardiac hypertrophy, and diabetes2, 3. 
Inhibition of mTOR signaling through either genetic or pharmaceutical approaches has been shown to slow aging 
in a variety of biological species4–16, indicating that mTOR is an important modulator of aging17.
mTOR exists in two complexes in mammalian cells, mTORC1 and mTORC2 (mTOR complex 1 and 2), with 
distinct roles in the regulation of biological processes18, 19. mTORC1, which is sensitive to the drug rapamycin, 
regulates ribosome biogenesis, protein translation and autophagy by phosphorylation of downstream targets, 
including S6K1, 4EBP1, and ULK120. mTORC2, which is less sensitive to rapamycin, regulates the cytoskeleton 
and metabolism through the phosphorylation of a set of targets distinct from mTORC1, including AKT, PKCα, 
and SGK1.
mTORC1 is negatively regulated by a critical upstream inhibitor complex, the TSC1/2 complex21. Mutation of 
TSC1 or TSC2 leads to tuberous sclerosis, an autosomal-dominant genetic disease with the formation of benign 
tumors in multiple organ systems associated with hyperactivation of mTOR signaling22. TSC1/2 complex inhibits 
specifically mTORC1 by stimulating the conversion of a mTORC1 activator Rheb from an active form Rheb-GTP 
to an inactive form Rheb-GDP23. Interestingly, TSC1/2 has also been found to physically interact with and activate 
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mTORC2, independent of Rheb24. TSC1/2 has been described as a molecular switchboard for multiple signals to 
activate or inhibit mTORC1 activity21, including growth hormone (insulin-IGF-Akt pathway), stresses (ERK/
RSK), energy (the AMPK pathway), hypoxia (Redd1), and cytokines (IKKβ/NFκB). Because of its important 
role in mTOR signaling, animal models with TSC1/2 deletion or overexpression could be very useful for further 
understanding the role of mTOR signaling in different diseases and in aging. Previous study demonstrated that 
overexpression of TSC1 or TSC2 increased lifespan in Drosophila12. However, transgenic mammalian models of 
TSC1/2 have not been reported in aging studies, although a mouse model with muscle-specific overexpression of 
TSC1 or TSC2 has been reported to develop muscle atrophy, depending on the levels of transgene expression25. 
Besides its involvement in mTOR signaling, TSC1/2 has also been reported to function independently of mTOR26. 
It is therefore important to know the role of TSC1/2 in health and aging in both mTOR-dependent and –inde-
pendent manner.
To help understand the role of TSC1/2 in health and aging, we initiated a study to establish a TSC1 transgenic 
mouse model, which was designed to overexpress a human TSC1 full length gene ubiquitously. Our study found 
that Tsc1tg mice exhibit alterations in multiple signaling pathways and biological processes that are associated with 
the mTOR-TSC1/2 axis, improvements in overall health, and specifically in females an improvement of survival.
Results
Generation of TSC1 transgenic mice. Transgenic mice with hTSC1 expression were generated using the 
construct described in the materials and methods section (Fig. 1a). The integration of the transgene of hTSC1 was 
first confirmed in the founders and its offspring by detecting hTSC1 DNA using genomic DNA isolated from the 
tail of transgenic mice. As shown in Fig. 1b, the presence of the lower band which is specific for hTSC1 confirms 
the presence and transmission of hTSC1 gene in transgenic mice (the top band is the endogenous mouse TSC1). 
The expression of hTSC1 gene was subsequently confirmed by western blot analysis using TSC1 specific antibody. 
As shown in Fig. 1c, the expression of TSC1 protein increased approximately 30% in multiple tissues from Tsc1tg 
mice, including the heart, kidney, liver, and skeletal muscle. However, due to high levels of endogenous mouse 
TSC1 expression, the level of hTSC1 protein expression did not significantly altered the overall TSC1 protein pool 
in the brain of transgenic mice. Noticeably, the much higher level of endogenous TSC1 protein in adult mouse 
brain relative to other tissues is similar to what has been reported in human tissues27. The relatively small increase 
of TSC1 in the brain did not significantly affect downstream signaling and brain function as described in later 
sections of this report. The hTSC1 protein was still detectable in aged Tsc1tg mice (24–30 months of age) (liver and 
heart shown in, detected using a hTSC1-specific antibody), indicating a persistent expression of hTSC1 transgene 
in transgenic mice during aging.
Figure 1. Generation of Tsc1tg mice. (a) Diagram of DNA construct used for generating hTSC1 transgenic mice. 
pUbC: ubiquitin C promoter. (b) Detection of hTSC1 transgene by PCR using genomic DNA isolated from the 
tail of one of the founder lines. Tg – hTSC1 transgenic founder #1; WT – wild type pups; (+) – positive control 
DNA for hTSC1. (c) Quantification of TSC1 protein expression in different tissues of Tsc1tg mice using western 
blot (n = 6 mice/group). B – brain; L – liver; H – heart; K – kidney; M – skeletal muscle. The asterisks indicate 
statistical significance between Tsc1tg and wild type mice (*p < 0.05).
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Phenotyping of Tsc1tg mice. A high incidence of infant/newborn death was observed in Tsc1tg mice, 
with the survival rate of newborns around 50%. We suspect that the levels of hTSC1 transgene expression may 
be high in these groups of neonates, leading to the abnormally high neonatal death rate. We then performed 
quantitative real-time PCR analysis of hTSC1 transcription in the neonates. We found that the levels of hTSC1 
mRNA were indeed significantly higher in a subpopulation of the dead neonates that were examined in this study 
(Figure S2A).
The breeding is successful and the litter size is not different from wild type mice (Supplemental Figure S2B). 
The average litter size is 4–5 for the following different breeding schemes: crossing wild male with transgenic 
female, or crossing transgenic male to wild type female, or crossing transgenic male to transgenic female mice. 
The average frequency of births is about one per month for all the aforementioned breeding schemes. The gender 
ratio of the offspring is normal (close to 1:1). When using homozygous male Tsc1tg mice to breed with wild type 
female mice or vice versa, the frequency of hemizygous Tsc1tg mice is close to 50%, indicating a normal Mendelian 
ratio in the transgene inheritance.
The surviving Tsc1tg pups developed without obvious gross abnormality. The body weight and body composi-
tion was similar between wild type and Tsc1tg mice at younger ages in both sexes. However, female Tsc1tg mice had 
a small but significant reduction of lean body mass and increase of fat mass (as a percentage of body weight) at 
advanced ages (>20 months) than age-matched wild type control littermates (Fig. 2a). Male Tsc1tg mice, however, 
display no significant difference from age-matched wild type mice in body composition at any ages.
After normalizing the values against young mice, only significant age-associated changes between female 
Tsc1tg mice and wild type mice are the lean body mass ratio (Fig. 2b). The changes of fat mass and whole body 
weight from young to old mice were similar between both male and female Tsc1tg mice and wild type mice.
Figure 2. Body weight and composition. Body weight and composition of mice at different ages (specified in 
the figure) were determined using magnetic resonance imaging approach as described in the method section. 
(a) Body weight, lean and fat mass to body weight ratio. (b) Body weight, lean and fat mass normalized to 
young mice with the same gender and genotype. Male: 5–8 m mice, n = 17 for WT, n = 13 for TSC1tg; 20–22 m 
mice, n = 18 for WT, n = 10 for TSC1tg. Female: 12–14 m mice, n = 14 for WT, n = 15 for TSC1tg; 20–22 m mice, 
n = 12 for WT, n = 19 for TSC1tg. The asterisks indicate statistical significance between Tsc1tg and wild type mice 
(*p < 0.05).
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We further tested several behavioral and cognition parameters. No significant differences were detected 
between Tsc1tg mice and age-matched wild type mice in grip strength (Figure S2C), passive avoidance 
(Figure S2D), and motor neuron nerve conductivity (Figure S2E).
Tsc1tg mice have moderate but significant changes in multiple signaling pathways. Because 
TSC1 functions as a complex with TSC2 to inhibit mTOR signaling by preventing the degradation of TSC228, 
we first investigated whether overexpression of TSC1 leads to stabilization of TSC2 in Tsc1tg mice. As shown 
in Fig. 3a, the levels of TSC2 proteins were indeed higher in heart and liver from Tsc1tg mice than age-matched 
wild type control littermates, suggesting that overexpression of TSC1 was able to stabilize TSC2 in Tsc1tg mice. 
However, the level of TSC2 did not change significantly in the brain of Tsc1tg mice.
Next, mTORC1 signaling was investigated by quantifying the phosphorylation of three mTORC1 subunits, 
S6K1, ULK1 and 4EBP1, as well as ribosome subunit 6 (S6), which is a substrate for S6K129. As shown in Fig. 3b and c, 
the levels of phosphorylation of S6K1(T389), ULK1(S757), 4EBP1(T37/46), and S6(S235/236) decreased mod-
erately but significantly (15–30%) in different tissues from Tsc1tg mice, including the heart and liver. Other tis-
sues, including the kidney, spleen and skeletal muscle also exhibit reduced phosphorylation in S6 (Figure S1A). 
Correlated to the reduction of mTORC1 signaling, the conversion of LC3 (LC3II/LC3I ratio), which is a marker 
of autophagy30, increased moderately but significantly in the heart, kidney, liver, skeletal muscle, and spleen, 
suggesting an enhancement of autophagy in these tissues (Figs 3c and S1B). In the brain, the mTORC1 signaling 
and the ratio of LC3II/LC3I were not significantly altered in Tsc1tg mice when compared to age-matched wild 
type mice.
While mTORC1 signaling was reduced, the signaling pathway associated with mTORC2 appears to be 
enhanced in Tsc1tg mice, indicated by the increases of the phosphorylation of AKT at serine 473 and PCKα at 
serine 657, which are two known substrates for mTORC231. As shown in Fig. 4, the levels of phosphorylated 
AKT(S473) and PKCα(S657) increased moderately but significantly in the heart, liver, and skeletal muscle of 
Tsc1tg mice, suggesting an increase of mTORC2 activity. Interestingly, the phosphorylation of GSK3β at serine 9 
was also increased (Fig. 4c). Because GSK3β (S9) phosphorylation is mediated by AKT, our data further support 
the activation of mTORC2 in Tsc1tg mice. However, the phosphorylation of ATK at threonine 308 was no signifi-
cantly affected in Tsc1tg mice (Figure S1D).
Food consumption, glucose tolerance and insulin sensitivity. Because mTOR signaling is associated 
with nutrition, energy metabolism and appetite, we next determined whether reduction of mTOR in Tsc1tg mice 
affected food consumption. Food consumption was measured for both male and female Tsc1tg mice at 4–6 months 
of age. As shown in Figure S3, both male and female Tsc1tg mice consumed similar amount of food per gram of 
body weight as that of age-matched wild type mice, indicating that a moderate reduction of mTOR signaling did 
not affect food consumption in young Tsc1tg mice. At advanced ages, both male and female Tsc1tg mice showed no 
alteration in the resting metabolic rate (RMR) and spontaneous activity (Supplemental Table S1) when measured 
at 18–20 months of age. However, during either light or dark cycle, the respiratory quotient (RQ) measured as the 
ratio between the volume of carbon oxide production and the volume of oxygen consumption in 18–20 month 
old female Tsc1tg mice is significantly higher than age-matched wild type littermates (Supplemental Table S1), sug-
gesting female Tsc1tg mice preferentially utilize carbohydrate energy sources over fat. No difference was observed 
in male Tsc1tg mice.
It has been reported previously that inhibition of mTOR signaling by rapamycin leads to glucose intolerance 
and insulin resistance32–35. We therefore compared the responses to glucose and insulin injection between Tsc1tg 
and wild type mice. First, the levels of blood glucose and insulin were measured. As shown in Figure S4A and S4B, 
the fasting blood glucose levels are not different between either young or old Tsc1tg mice and age-matched wild 
type mice. The plasma insulin level is also similar between female Tsc1tg mice and wild type mice under normal 
feeding conditions at both young and advanced ages (Figure S4C). We then compared the blood glucose clearance 
between Tsc1tg mice and age-matched wild type mice using GTT and ITT tests. As shown in Fig. 5a, female Tsc1tg 
mice at 22–24 months of age are similar in the clearance of blood glucose as age-matched wild type mice. Young 
Tsc1tg mice (4–6 month of age) also have similar responses to glucose injection as age-matched wild type mice 
(Figure S4D). Finally, Tsc1tg mice have similar insulin sensitivity as age-matched wild type mice at 22–24 months 
of age (Fig. 5b).
Tsc1tg mice are more tolerant to exhaustive exercise. mTOR signaling is associated with energy 
metabolism, hence animal physical activity and strength36. One of the aging manifestations is the decline of 
physical activity and strength with age37. In this study, we investigated the tolerance of Tsc1tg mice to the treadmill 
exhaustive exercise running test at different ages. As shown in Fig. 6a, both male and female Tsc1tg mice have a 
statistically significant increase in treadmill running capacity at both young and old ages (4–6 and 22–27 months, 
respectively) compared to age-matched wild type littermates. Tsc1tg mice reached exhaustion and collapsed signif-
icantly later than age-matched wild type control mice. Blood lactate level was measured before and after treadmill 
running. The increase of blood lactate level in Tsc1tg mice after exercise is significantly less than that of wild type 
control mice (Fig. 6b).
Tsc1tg mice are more resistant to cardiac hypertrophy. Down regulation of mTOR signaling by rapa-
mycin has been shown to reduce the development of cardiovascular diseases such as cardiac hypertrophy38–45. 
We therefore tested whether increased expression of TSC1 could affect cardiac function in a similar manner. 
Without any challenge, the cardiac function is similar between Tsc1tg mice and age-matched wild type littermates 
(data obtained from mice at 6–8 months of age, Supplemental S2). However, after challenged with isoproterenol, 
a compound used to induce pathological cardiac hypertrophy46, Tsc1tg mice developed significantly less cardiac 
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Figure 3. Effects of TSC1 overexpression on cell signaling. Proteins extracted from different tissues were 
subjected to western blot analysis as described in the methods section (n > = 6 mice at 4–6 month of age for 
each genotype, includes both male and female mice). (a) TSC2 protein expression in different tissues. (b) mTOR 
signaling was monitored as the level of phosphorylation of S6K1 (threonine 389), ULK1 (serine 757), 4EBP1 
(threonine 37/46), and S6 (serine 235/236). (c) The detection of autophagy related changes: Phosphorylation of 
ULK1 (serine 757) and the conversion of an autophagy marker LC3 from LC3I to LC3II (LC3II/LC3I ratio). WT 
– wild type littermates; TSC1 - Tsc1tg mice. B – brain; L – liver; H – heart. The band intensity was normalized to 
wild type mice in each group. The asterisks indicate statistical significance between Tsc1tg and wild type mice in 
a specific tissue (*p < 0.05).
www.nature.com/scientificreports/
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Figure 4. Changes of mTORC2 related signaling in TSC1tg mice. (a) Phosphorylation of ATK at serine 473 and 
(b) Phosphorylation of PCKα at serine 657 in the heart, liver and skeletal muscle (SKM). (c) Phosphorylation of 
GSK3β at serine 9 in liver and heart. The protein band intensity was normalized to wild type mice in each group. 
The asterisks indicate statistical significance between Tsc1tg and wild type mice (*p < 0.05, n = 6 for each group, 
includes both male and female mice).
Figure 5. Glucose tolerance and insulin sensitivity in TSC1tg mice. (a) Glucose tolerance test (GTT) in 22–24 
month old female mice (n = 6 mice in each group). (b) Insulin sensitivity test (ITT) in female 22–24 month 
old mice (n = 6 mice in each group). Blood glucose was measured every 15 or 30 minutes after either glucose 
or insulin injection. The left graphs corresponding to each graph on the left are plotted after normalizing to 
the levels of blood glucose just prior to the injection. WT – wild type mice (white square); TSC1 - TSC1tg mice 
(Solid black circle).
www.nature.com/scientificreports/
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hypertrophy with better preservation of cardiac function than age-matched wild type littermates. As shown in 
Fig. 7a, after isoproterenol injection, female Tsc1tg mice exhibited significantly less increases in heart size than 
age-matched wild type littermates at both young (6–8 month), middle (10–14 month), and advanced ages (22–24 
month). Similar results were also observed in male Tsc1tg mice. The ejection fraction is significantly smaller in 
Tsc1tg mice than in wild type littermates as measured post isoproterenol challenge (data obtained from mice of 
6–8 months of age were shown) (Figure S5).
Histological examination revealed that TSC1tg mice had significantly less fibrosis and collagen deposition in 
the heart after challenged with isoproterenol. As shown in Fig. 7b, the appearance of collagen fibers in the heart 
of female TSC1tg mice after ISO challenge increased significantly less than that of wild type control mice in all 
three age groups: young (6–8 months of age), middle (10–14 months of age), and old (22–24 months of age). The 
changes of collagen content after ISO challenge vs. saline control in each age group was quantified, as shown in 
the right of the histological staining images, to reflect the quantitative difference between TSC1tg mice and wild 
type control mice across different ages. These data further suggest that moderate TSC1 overexpression is benefi-
cial to the heart against pathological hypertrophic stimulation.
Several signaling pathways involved in fibrosis and inflammation in the heart underwent changes in patterns 
that are significantly different between Tsc1tg mice and wild type mice at advanced ages and after ISO challenge. 
As shown in Fig. 8, two extracellular matrix metalloproteinases involved in cardiac remodeling, MMP2 and 
MMP947, exhibit different patterns of changes between Tsc1tg and wild type mice at 22–24 months of age. The 
levels of cardiac MMP2 in aged wild type mice are significantly higher than that in Tsc1tg mice, while the levels 
of MMP9 remain similar between wild type and Tsc1tg mice. After ISO challenge, MMP2 increased significantly 
in both wild type and Tsc1tg mice, while MMP9 increased only significantly in wild type mice. In addition, FGF2 
(Fibroblast Growth Factor 2), a growth factor involved in cardiac remodeling48, is expressed in significantly higher 
levels in aged wild type mice than Tsc1tg mice. After ISO injection, FGF2 increased further in wild type mice and 
also increased significantly in Tsc1tg mice. Finally, two pathways that are involved in inflammatory responses, the 
NFkB and Stat3 signaling pathways49, were less activated in the hearts of aged as well as ISO-challenged Tsc1tg 
mice than that in wild type mice, indicated by the lower levels of phosphorylation of NFkBp65 and Stat3. Our data 
therefore suggest that the hearts of aged as well as ISO-challenged Tsc1tg mice have less fibrosis and inflammation 
than wild type mice.
Figure 6. Exhaustive exercise on treadmill. (a) Running distance on treadmill till exhaustion for male and 
female mice at different ages (6–8, 24–27(female), 22–26 (male) months of age; n = 8 mice for each group). (b) 
Blood lactate levels before and after treadmill running test (n = 8 mice for each group). The asterisks indicate 
statistical significance between Tsc1tg (black solid bar or circle) and wild type mice (white blank bar or circle) 
(*P < 0.05). WT – wild type mice; TSC1 - Tsc1tg mice.
www.nature.com/scientificreports/
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Survival of TSC1tg mice. A survival study was conducted using both male and female mice. As shown in 
Fig. 9 and Table S2, the survival is different between female and male TSC1tg mice. The lifespan of female TSC1tg 
mice is extended significantly (p = 0.028, one-sided Log-rank test), with an increase of 12.3% in median lifespan 
(893 vs. 795 days for TSC1tg mice and wild type mice, respectively). However, the survival of male TSC1tg mice is 
not significantly different from that of wild type mice (p = 0.195, one-sided Log-rank test), indicating a sex differ-
ence in the effect of TSC1 overexpression on lifespan extension.
Discussion
In the current study we developed and characterized for the first time a mouse model that overexpresses TSC1 
ubiquitously. Our data demonstrated that: (1) TSC1 overexpression did not lead to adverse health conse-
quences to mice; (2) In fact, Tsc1tg mice are more tolerant to exhaustive exercises and more resistant to cardiac 
hypertrophic challenge during aging than wild littermates; (3) the survival of female Tsc1tg mice is significantly 
improved. These data suggest that TSC1 transgenic animal models could serve as new tools to understand the role 
of the TSC1/2 complex (mTOR related vs. non-mTOR related roles) in aging and age-associated diseases in vivo.
Figure 7. Cardiac function analysis after isoproterenol injection. (a) Heart size (ratio to body weight) in young 
(6–8 month, n = 8 for each group), middle aged (10–14 months, n = 8 WT, n = 12 TSC1tg), and old (22–24 
months, n = 13 WT, n = 15 TSC1tg) female mice before and after isoproterenol challenge. White bar – mice with 
saline; black bar – mice with isoproterenol injection. Asterisks (*p < 0.05 and **p < 0.01) indicate statistical 
significance between isoproterenol injected mice and saline injected mice. Ampersand (#p < 0.05) indicates 
statistical significance in the degree of hypertrophy after isoproterenol injection between Tsc1tg mice and wild 
type mice. (b) Histological examination of left cardiac tissue from young (6–8 month), middle aged (12–14 
month), and old (22–24 month) female mice using Picrosirius Red Staining as described in the method section 
(n = 6 mice in each group). Collagen content changes during hypertrophy were calculated as a percentage of 
collagen content after isoproterenol against saline injected mice of the same genotype. Asterisks (*p < 0.05) 
indicate statistical significance between Tsc1tg mice and wild type mice.
www.nature.com/scientificreports/
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TSC1/2 is an important upstream regulator of mTOR signaling, which is a molecular switchboard for mTOR 
to respond to multiple signals21. Deregulated mTOR signaling has been implicated in major diseases, including 
cancer, metabolic disorders, neurological diseases, and inflammation3. Inhibition of mTOR using either genetic or 
pharmaceutical approaches has been found to extend lifespan in a wide spectrum of species from yeast to mam-
mals6–16, 50. Previously, it has been shown that overexpression of TSC1 or TSC2 extended lifespan in Drosophila 
and improved cardiac function12. Our study using mouse model provide new evidence to support the notion that 
intervention in the gene expression of TSC1/2 complex can alter animal survival and health.
The observed gender differences in lifespan extension in Tsc1tg mice is not surprising. In fact, it is a common 
phenomenon observed in many genetic and pharmacological models51. Such gender differences in lifespan exten-
sion by mTOR inhibition have been reported in different animal models. Deletion of S6K1 in mice, a downstream 
target of mTORC1, led to significant increase of lifespan in female but not male mice16. Heterozygous deletion of 
both mTOR and mLST8 in mice led to lifespan extension in female but not male mice33. Pharmacological inhibi-
tion of mTOR in mice using rapamycin revealed that rapamycin has greater effect on female lifespan than on male 
lifespan6, 7, 9. It will be important to understand the mechanisms underlying this gender differences in lifespan 
extension by the intervention of mTOR signaling.
Although earlier studies using continuous rapamycin administration had some unexpected negative effects 
on mice, rats or human cells, including glucose intolerance34, 35 and insulin resistance32, 33, we did not observe 
changes in glucose homeostasis and metabolism in Tsc1tg mice, which is consistent with several recent studies. 
Wu et al.10 demonstrated that reduced mTOR expression in mice with mTOR hypomorphic alleles did not affect 
glucose tolerance, overall metabolic rate and energy expenditure. Lamming’s group recently demonstrated that 
intermittent rapamycin feeding did not alter glucose homeostasis52. Bartke’s group reported that the metabolic 
Figure 8. Fibrosis and inflammatory response in the heart of aged mice and the heart of mice after 
isoproterenol challenge. (a) Western blot analysis of NFκB, Stat3, FGF2 and MMP2/9 in heart protein extracts 
from old female mice (22–24 months of age, n = 6). (b) Quantification of protein band intensity (n = 6). WT – 
wild type mice; TSC1 - Tsc1tg mice. White bar – saline-injected mice; black bar – isoproterenol-injected mice. 
Asterisks (*p < 0.05 and **p < 0.01) indicate statistical significance between isoproterenol injected and saline 
injected mice of the same genotype as indicated in the graph.
www.nature.com/scientificreports/
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changes in rapamycin-fed mice was dependent on the duration of rapamycin treatment53. Insulin resistance and 
glucose intolerance occurred at short term rapamycin treatment (2 weeks), while insulin resistance disappeared 
after long term treatment (20 weeks).
Mice with rapamycin administration has also been reported to develop testicular degeneration and cataracts50. 
However, the male Tsc1tg mice are fertile with similar breeding capacity as wild type mice, indicating no testicular 
degeneration in male Tsc1tg mice. Interestingly, there is a noticeable difference in the survival rate of newborns 
between male Tsc1tg mice and wild type mice. The neonatal death is more than 50%, which is significantly higher 
comparing to wild type mice with less than 30% neonatal death rate. We speculate that at least two causes led to 
this abnormal neonatal death rate in Tsc1tg mice. First, the TSC1 transgene expression may be much higher in 
some embryos during development that leads to greater suppression of mTOR signaling. Because mTOR is crit-
ical to animal development31, the greater level of suppression of mTORC1 in the embryos may eventually lead to 
their demise. Second, the suppression of mTORC1 signaling may affect the mother’s nursing function (e.g., lack 
of enough milk for all the pups, etc.), which leads to the death of some pups. Some studies have linked mTOR 
signaling to milk production and lactation54, 55. Our data suggest that higher levels of hTSC1 expression during 
development may be one of the causes of the high neonatal death rate. Therefore, a different TSC1 transgenic 
animal model may serve the purpose better, such as an inducible model that expresses TSC1 or TSC2 transgene 
in a timely controlled manner to overcome its negative effect on development.
A previous study using rapamycin in C57BL/6 mice showed that male mice fed rapamycin experienced a 
reduction in whole body mass initially (from 19 to 25 months), while female mice did not9. Neither male nor 
female Tsc1tg mice lose weight in our study. Interestingly, female Tsc1tg mice have altered body composition with 
increased fat mass and decreased lean body mass (ratio to whole body mass) at advanced ages. The increase of fat 
deposit has been reported by Liu et al.56 in rapamycin- and high fat-fed male mice. However, Liu’s study did not 
report the effect of rapamycin on fat deposit in female mice. The cause of the gender difference in body compo-
sition in Tsc1tg mice is unknown. It may be due to the intrinsic gender differences of mTOR signaling in different 
tissues with age57. The change in body composition in female Tsc1tg mice is probably not due to food intake as 
being reported in mice fed rapamycin9, because we did not observe a significant difference in food consump-
tion between Tsc1tg mice and wild type mice. The alteration of the ratio between fat mass and lean body mass in 
female Tsc1tg mice could be due to the changes of metabolism in fat usage and deposit. We further hypothesize 
that sex hormones may be involved in the differences between female and male Tsc1tg mice. Nonetheless, the 
underlying mechanisms by which overexpression of TSC1 leads to more fat mass in female Tsc1tg mice remains 
to be answered. It is worth to point out that the small gender differences did not affect the physiological outcomes 
tested in this study, including grip strength, motor neuron function, and cognition.
Although mTOR signaling plays an important role in cardiac development and function58, the heart appears to 
develop normally in Tsc1tg mice. Reduction of mTOR signaling has been shown to be beneficial to cardiac health 
and aging, especially cardiac hypertrophy41–43, 59, 60. Tsc1tg mice have increased resistance to cardiac hypertrophy 
Figure 9. Lifespan analysis of TSC1tg mice. Survival curves are shown for female and male mice separately (67 
females: 27 and 40 for wild type and TSC1tg mice separately; 67 males: 32 and 35 for wild type and TSC1tg mice 
respectively). The survival curve for female mice is significant, while not for male mice (p = 0.0282 for female 
mice; p = 0.195 for male mice, determined by one sided Log-rank test analysis).
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challenge and are more resistant to exhaustive exercises, suggesting an improved cardiac function/health in Tsc1tg 
mice. Tsc1tg mice developed less fibrosis and inflammation in the heart during aging and when challenged with 
ISO, suggesting moderate TSC1 overexpression in our study improves cardiac health during aging. Our data 
further indicate that modulation of inflammation by TSC1 may play a very important role in aging and in cardiac 
response to hypertrophic stimulation. However, mTOR signaling has also been shown to be required for the pro-
tection of heart during ischemia/reperfusion (I/R) injury61, 62. Therefore, it is important to test whether reduction 
of mTOR signaling chronically by either genetic approaches or pharmaceutical approached will negatively affect 
the cardiac response to I/R injury during aging.
Although it has been shown to primarily affect the activation of mTORC1, TSC1/2 complex has also been 
reported to be required for proper activation of mTORC263. The present study observed a small but significant 
increase of the phosphorylation of two mTORC2 substrates, AKT at serine 473 and PCKα at serine 657, suggest-
ing the enhancement of mTORC2 signaling in Tsc1tg mice. The elevation of mTORC2 activity in Tsc1tg mice may 
partially explain the resistance of Tsc1tg mice to cardiac stresses and exhaustive exercises, which is in agreement 
with a recent study demonstrating that mTORC2 is required for normal cardiac function64.
It is worth to note that mTOR signaling was not altered in the brain of Tsc1tg mice. This is due to the expression 
of high levels of endogenous TSC1 in the brain tissue, which wipes out the effect of exogenous TSC1 on mTOR 
signaling in the brain. This could be the primary reason that we did not observe any significant changes in neu-
rological tests. This problem can be addressed using brain tissue specific overexpression of TSC1/2 with a strong 
promoter. Although it is unfortunate that we did not observe neurological changes in Tsc1tg mice, this study still 
proves an important point that reduction of mTOR signaling in tissues other than the brain could still improve 
health and lifespan.
Finally, TSC1/2 complex has been found to function independently of mTOR26. Therefore, it is likely that the 
mTOR-independent function of TSC1/2 may also contribute to the lifespan extension and health improvement 
in Tsc1tg mice. It will be of great interest to identify those mTOR-independent functions of TSC1/2 that may be 
involved in health and aging in future studies.
In conclusion, our study has demonstrated that overexpression of TSC1 could extend lifespan and lead to 
better health in mice, particularly cardiac health.
Materials and Methods
Animals. All mice were fed a standard NIH-31 chow (Teklad Diet LM485; Harlan Teklad, Madison, WI) ad 
libitum and maintained under barrier conditions in micro-isolator cages on a 12-h dark/light cycle. For tissue 
collection, animals were sacrificed by CO2 inhalation followed by cervical dislocation, and the tissues were imme-
diately excised and placed in liquid nitrogen.
All the animal procedures performed confirm to NIH guidelines and were approved by the institute animal 
care and use committee (IACUC) of the University of Texas Health Science Center at San Antonio, San Antonio, 
Texas.
Generation of hTSC1 transgenic mice. Full-length hTSC1 cDNA (a kind gift from Dr. Kun-Liang Guan 
from the University of California at San Diego) was restriction digested and ligated into the mammalian expres-
sion vector pUB6-His (Invitrogen, CA) for ubiquitous expression under the control of ubiquitin C promoter 
(Fig. 1a). After the construct was confirmed by restriction digestion and DNA sequencing, the expression of 
hTSC1 protein was further determined and confirmed by transfecting in vitro tissue cultures. Transgenic mice 
were subsequently generated using this construct in the Transgenic Animal Model Core facility in University of 
Michigan. The genotypes of all offspring were determined by PCR amplification of mouse tail DNA using specific 
primers: 5′-TCAGTGTTAGACTAGTAAATTG-3′, and 5′-GCTGTTTCCCAGACTGTG-3′ for 35 cycles (94 °C 
15 seconds, 52 °C 30 seconds, and 72 °C 50 seconds). Expression of hTSC1 in transgenic mice was determined at 
both transcription and protein levels using reverse transcriptional polymerase chain reaction (RT-PCR) with 
specific primers and western blotting analysis with TSC1 specific antibody respectively.
Body composition measurement. Body composition and food consumption of transgenic mice and 
wild type littermates was determined as described elsewhere65. Briefly, body composition was measured using 
quantitative Magnetic Resonance Imaging (EchoMRI 3-in-1 System, Houston, TX), following the manufacturer’s 
recommendations.
Western blot analysis. Protein expression and phosphorylation was determined by western blot analy-
sis. Briefly, tissues were homogenized in ice-cold homogenization buffer (50 mM Tris-HCl, pH7.5, 0.5% Triton 
X-100) with the addition of cocktails of protease inhibitors and phosphatase inhibitors (Roche, Indianapolis, IN), 
followed by centrifugation at 10,000 g for 20 minutes at 4 °C. The supernatant was transferred to a new tube and 
protein concentration was determined using Bio-Rad protein assay reagents (Bio-Rad, CA). Equal amount of 
protein was separated by SDS-PAGE gel electrophoresis and transferred to nitrocellulose membrane. Individual 
protein was detected with species specific primary antibodies, followed by species specific secondary antibody 
conjugated with horse radish peroxidase (HRP). Primary antibodies used in this study are specific for: TSC1 
(Cat. #4906), TSC2 (Cat. #3612), pTSC2(T1462) (Cat. #3611), S6 (Cat. #2217), pS6(Ser235/236) (Cat. #4856), 
4EBP1 (Cat. #9452), p4EBP1(Thr37/46) (Cat. #9459), S6K1 (Cat. #9202), pS6K1(Thr389) (Cat. #9205), Akt (Cat. 
#9272), pAkt(Ser473) (Cat. #4060), pAkt(Thr308) (Cat. #9275), GSK3β (Cat. #9315), pGSK3β(Ser9) (Cat. #9336), 
ULK1 (Cat. #8054), Phospho-ULK1 (Ser757) (Cat. #6888), and LC3 (Cat. #2775) (all from Cell Signaling, Beverly, 
MA); hTSC1 (Epitomics, Cat. #1744-1; Cell Signaling, Cat. #3635); PKCα (Cat. ab32376), pPCKα(Ser657) (Cat. 
ab180848) (from Abcam, Cambridge, MA); GAPDH (from Santa Cruz Biotech., Dallas, Texas). The band signal 
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was captured by a phosphor-imager (Typhoon scanner, GE, Piscataway, NJ) and quantified by the Image-Quant 
software (GE, Piscataway, NJ).
Glucose tolerance test (GTT) and insulin tolerance test (ITT). GTT were performed in mice (6 mice 
in each group) fasted overnight. The mice were weighed next morning and the dose of glucose were calculated 
for each mouse. Blood glucose was measured before the injection as baseline fasting blood glucose level. Glucose 
(20% solution in saline) was injected intraperitoneally at a dose of 1.5 mg kg−1 body weight. Blood glucose levels 
were measured using hand-held glucometer (One Touch Ultra) every 15 minutes post glucose injection.
Insulin tolerance test was conducted in mice (6 mice in each group) after 6 hours fasting. Insulin (0.25 IU solu-
tion in saline) was administered intraperitoneally at a dose of 0.75 IU/g body weight. Blood glucose levels were 
measured at 15, 30, 40, 60, 90, and 120 minutes post insulin injection.
Insulin levels were determined in frozen plasma samples obtained from terminally sacrificed mice by ELISA 
following manufacturer’s instructions (Crystal Chem, Downer’s Grove, IL).
Treadmill running test. Mice were subjected to exhaustive exercise test on a treadmill as described else-
where66. Briefly, the mice from all groups were initially acclimated to treadmill environment by performing a daily 
running session at 7 m/min for 15 min during three successive days (adaptation period). Then, the mice run on 
a treadmill to the point of exhaustion with the following protocol: the starting speed was 9 m/min; the speed was 
increased 2 m/min every 3 min until it reached 17 m/min; thereafter, the speed continued to increase by 1 m/min 
every 3 min until exhaustion. Exhaustion was defined as the point at which a mouse refused to run despite being 
given mild touches.
Blood lactate levels were measured using a lactate assay kit from Abcam following the manufacturer’s instruc-
tion. Blood was collected from the tail before and after exercises.
Isoproterenol-induced cardiac hypertrophy. Isoproterenol was injected peritoneally in mice at 30 mg·k-
g−1day−1 for 7 days. Control mice were injected with vehicle only (saline). At day 8, mice were sacrificed. The 
heart were perfused with saline and dissected into three parts perpendicularly: the apex tip and the aorta proxi-
mal part was flash frozen in liquid nitrogen and stored in −80 °C for protein and RNA isolation; the mid section 
was fixed in formalin for histological study.
Histological examination of heart tissue. Heart tissues were removed and kept in 10% formalin 
solution. After routine histologic procedures, they were embedded into paraffin; 4–5 μm thick sections were 
taken from paraffin-embedded tissues and stained with Picrosirius Red method. Briefly, the paraffin sections 
were de-waxed and hydrated, followed by staining the nuclei with Weigert’s haematoxylin (Sigma-Aldrich) for 
8 minutes, and washing for 10 minutes in running tap water. Then the sections were stained in picro-sirius red 
(Sigma-Aldrich) for one hour, followed by washing in two changes of acidified water. After dehydrated in three 
changes of 100% ethanol, the sections were cleared in xylene and mounted in a resinous medium. The stained 
sections were examined under a Zeiss Axio Lab A1 light microscope (Carl Zeiss, Germany). In general, five heart 
sections from each mouse out of six mice in each group were examined for fibrosis and collagen content.
Animal lifespan studies. A total of 67 female mice (27 wild type, 40 Tsc1tg mice) and 67 male mice (32 wild 
type, 35 Tsc1tg mice) were used in the lifespan study. Mice were maintained in pathogen-free barrier conditions 
with 5 mice per cage and were permitted to live out their lives until death due to natural causes with occasional 
censoring of mice with severe diseases. The survival study was terminated earlier before its completion. The mice 
that were alive but sacrificed at the termination of the study (18 males on September 16 2014 and 8 females on 
September 9 2014) were considered censored. Survival data was analyzed using one-sided Log-rank test.
Statistical analysis. Data were expressed as means ± standard error. Student’s t-test or one-way ANOVA 
was used to compare between transgenic and wild type mice to determine statistical significances. A p-value of 
less than 0.05 was considered statistically significant. Survival data was analyzed using one-sided Log-rank test.
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